Strategic Partnership Announced Between AAOS and OREF

The American Academy of Orthopaedic Surgeons (AAOS) and the Orthopaedic Research and Education Foundation (OREF) announced a strategic partnership to help narrow the gap between clinical research funding and prioritized clinical research needs in musculoskeletal care. The partnership aims to highlight areas of clinical research for which there is a need for increased, targeted funding to evaluate the effectiveness of various orthopedic interventions and ultimately improve the quality of care for patients.

“Orthopaedic surgeons rely on the AAOS clinical practice guidelines to provide high-quality, unbiased evidence-based recommendations for a variety of musculoskeletal treatments. However, there are several orthopedic interventions for which there is a dearth of evidence evaluating their effectiveness,” said Kristy Weber, MD, FAAOS, AAOS past president. “Together with our partners at OREF, we have designed a unique funding opportunity for clinical researchers looking to design and execute studies across musculoskeletal specialties­­, including orthobiologics. To help jump-start the effort in 2020, the AAOS is making an initial financial investment.”

The inaugural list of clinical research topics prioritized by the AAOS includes research addressing the efficacy of biologics for the treatment of orthopedic diseases with a particular focus on platelet-rich plasma and growth factor injections for full-thickness rotator cuff tears and osteoarthritis of the knee. Additionally, the AAOS has prioritized funding for clinical research reviewing the effect of tobacco, vaping, and/or marijuana use on postoperative outcomes for total joint arthroplasty, as well as the effectiveness of antibiotic bone cement for prevention of periprosthetic joint infections. The OREF Research Grants Committee will finalize the selection of topics in the Request for Applications (RFA) scheduled to be released later this year.

“OREF was founded on the belief that to advance orthopedic practice, we must advance orthopedic knowledge,” said Richard F. Kyle, MD, OREF president. “We are delighted to collaborate with the AAOS to fund investigational grants that will catalyze research and play a key role in the future of orthopedic care.”

For more information about the AAOS’ quality programs and guidelines, including the AAOS’ recent investment in evidence-based educational content and symposia for orthobiologics, visit AAOS.org/quality. Donors interested in earmarking funds to further enable AAOS-prioritized clinical research needs within musculoskeletal healthcare can contribute to the OREF/AAOS Clinical Research Gaps Fund. Go to oref.org/aaoscpg to make a secure online donation.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.